ClinicalTrials.gg

Program

pertuzumab

Also written as “Pertuzumab”, “Pertuzumab IV” and “Perjeta”.

Its studies are mostly in Breast Neoplasms · Ovarian Neoplasms · Carcinoma, Non-Small-Cell Lung · Stomach Neoplasms · Prostatic Neoplasms, led by 6 companies.

Furthest: phase 4, since May 13, 201546 company-led studies, 3 open or runningNext primary completion: Mar 28, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche411 open or runningphase 4since May 13, 2015Nov 15, 2001Mar 28, 2027phase 3 · NCT02320435
Cinnagen10 open or runningphase 3since Jun 22, 2021Jun 22, 2021none ahead
CSPC Pharmaceutical Group11 open or runningphase 3since Nov 25, 2022Nov 25, 2022none ahead
Mabscale11 open or runningphase 1since Apr 11, 2023Apr 11, 2023none ahead
Sarah Cannon Research Institute10 open or runningphase 2since Aug 27, 2014Aug 27, 2014none ahead
Zydus Lifesciences10 open or runningphase 3since Feb 26, 2022Feb 26, 2022none ahead

Also a collaborator on its studies: Daiichi Sankyo and roche-pharma-ag.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 33 studies since Nov 15, 2001.

  1. Aug 10, 2015Phase 2 study in Breast NeoplasmsHoffmann-La Roche · NCT02536339 · 40 enrolled · United States
  2. Oct 23, 2015Phase 3 study in Breast NeoplasmsHoffmann-La Roche · NCT02586025 · 329 enrolled · China, Korea, Republic of, Taiwan and more
  3. Mar 29, 2016Phase 1 study in Breast NeoplasmsHoffmann-La Roche · NCT02738970 · 88 enrolled · New Zealand
  4. Sep 7, 2016Phase 3 study in Breast NeoplasmsHoffmann-La Roche · NCT02896855 · 243 enrolled · China
  5. Apr 4, 2018Phase 3 study in Breast NeoplasmsHoffmann-La Roche · NCT03493854 · 500 enrolled · United States, Argentina, Belgium and more
  6. Apr 5, 2018Phase 2 study in Neoplasms, Unknown PrimaryHoffmann-La Roche · NCT03498521 · 529 enrolled · Australia, Austria, Brazil and more
  7. Sep 12, 2018Phase 2 study in HER2-Positive Early Breast CancerHoffmann-La Roche · NCT03674112 · 160 enrolled · United States, Argentina, Brazil and more
  8. Jul 17, 2019Phase 3 study in HER2-positive Early Breast CancerHoffmann-La Roche · NCT04024462 · 200 enrolled · China
  9. Jun 22, 2021Cinnagen's first study: phase 3 study in HER2-positive Breast CancerNew to CinnagenCinnagen · NCT04957212 · 214 enrolled · Iran, Islamic Republic of
  10. Feb 26, 2022Zydus Lifesciences's first study: phase 3 study in Breast NeoplasmsNew to Zydus LifesciencesZydus Lifesciences · NCT05283837 · 268 enrolled · India
  11. Jun 8, 2022Phase 3 study in Breast NeoplasmsHoffmann-La Roche · NCT05415215 · 346 enrolled · Argentina, Bosnia and Herzegovina, Brazil and more
  12. Nov 25, 2022CSPC Pharmaceutical Group's first study: phase 3 study in HER2-positive Breast CancerNew to CSPC Pharmaceutical GroupCSPC Pharmaceutical Group · NCT05720026 · 560 planned · China
  13. Apr 11, 2023Mabscale's first study: phase 1 study in Healthy MenNew to MabscaleMabscale · NCT05825781 · 114 enrolled · Russian Federation
  14. Nov 6, 2026Primary completion moved from 2026-12-31 to 2027-03-28Date moved laterphase 3 · +3 months · NCT02320435

Ahead

  1. Mar 28, 2027Primary completion: phase 3 study in Solid TumorsHoffmann-La Roche · NCT02320435

TargetBeta

ERBB2 →read by rule
“A humanized recombinant monoclonal antibody directed against the extracellular dimerization domain of the HER-2 tyrosine kinase receptor”NCIt, by rule
“Receptor protein-tyrosine kinase erbB-2 inhibitor”ChEMBL 37, by rule

Other programs on ERBB2

ProgramCompanyFurthest phaseStudies
TrastuzumabruleHoffmann-La Rochephase 485
trastuzumab deruxtecanruleDaiichi Sankyophase 449
tucatinibrulePfizerphase 425
disitamab vedotinRemeGenphase 336
trastuzumab rezetecanruleJiangsu HengRui Medicinephase 336
Lutetium-177Novartisphase 324
trastuzumab brengitecanSichuan Biokin Pharmaceuticalphase 321
Gallium-68Philogenphase 317
zongertinibruleBoehringer Ingelheimphase 315
Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102Sino Biopharmaceuticalphase 313
sunvozertinibruleDizal Pharmaceuticalsphase 312
anbenitamabCSPC Pharmaceutical Groupphase 312

Studies

All 46 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT05825781Healthy Men · Russian Federation1Active, not recruitingMabscaleJan 22, 2024114
NCT05720026HER2-positive Breast Cancer · China3RecruitingCSPC Pharmaceutical GroupAug 29, 2025560
NCT05415215Breast Neoplasms · Argentina, Bosnia and Herzegovina, Brazil and more3CompletedHoffmann-La RocheNov 20, 2024346
NCT05283837Breast Neoplasms · India3CompletedZydus LifesciencesSep 6, 2023268
NCT04957212HER2-positive Breast Cancer · Iran, Islamic Republic of3CompletedCinnagenMay 27, 2020214
NCT04024462HER2-positive Early Breast Cancer · China3CompletedHoffmann-La RocheDec 13, 2021200
NCT03674112HER2-Positive Early Breast Cancer · United States, Argentina, Brazil and more2CompletedHoffmann-La RocheFeb 24, 2020160
NCT03498521Neoplasms, Unknown Primary · Australia, Austria, Brazil and more2CompletedHoffmann-La RocheFeb 14, 2023529
NCT03493854Breast Neoplasms · United States, Argentina, Belgium and more3CompletedHoffmann-La RocheJul 4, 2019500
NCT02896855Breast Neoplasms · China3CompletedHoffmann-La RocheJun 27, 2018243
NCT02738970Breast Neoplasms · New Zealand1CompletedHoffmann-La RocheMay 31, 201888
NCT02586025Breast Neoplasms · China, Korea, Republic of, Taiwan and more3CompletedHoffmann-La RocheOct 23, 2017329
NCT02536339Breast Neoplasms · United States2CompletedHoffmann-La RocheMay 1, 201940
NCT02507375Carcinoma, Non-Small-Cell Lung · Belgium, Spain, United Kingdom1CompletedHoffmann-La RocheDec 200817
NCT02494596Solid Tumor · Spain, United Kingdom1CompletedHoffmann-La RocheSep 200519
NCT02490475Solid Tumor · Netherlands, United Kingdom1CompletedHoffmann-La RocheApr 200619
NCT02491892Breast Neoplasms · Australia, Belgium, Finland and more2CompletedHoffmann-La RocheApr 200579
NCT02480010Prostatic Neoplasms · France, Germany, Italy and more2TerminatedHoffmann-La RocheSep 200568
NCT02445586Breast Neoplasms · India4CompletedHoffmann-La RocheSep 26, 201852
NCT02320435Solid Tumors · Brazil, China, Costa Rica and more3Active, not recruitingHoffmann-La RocheMar 28, 2027154
NCT02291289Colorectal Neoplasms · Argentina, Belgium, Bosnia and Herzegovina and more2CompletedHoffmann-La RocheMay 31, 20191,044
NCT02229149Breast Neoplasms · United States2TerminatedSarah Cannon Research InstituteJan 202233
NCT02132949Breast Neoplasms · United States, Canada, Denmark and more2CompletedHoffmann-La RocheMar 3, 2016401
NCT02091141Neoplasms · United States2CompletedHoffmann-La RocheMay 24, 2023673
NCT02004093Ovarian Neoplasms · Belgium, Canada, Hungary and more2CompletedHoffmann-La RocheSep 2008149
NCT01774786Stomach Neoplasms · United States, Australia, Austria and more3CompletedHoffmann-La RocheDec 9, 2016780
NCT01684878Ovarian Neoplasms · Austria, Belgium, Denmark and more3CompletedHoffmann-La RocheJan 30, 2015208
NCT01674062Breast Neoplasms · Canada, France, Italy and more2CompletedHoffmann-La RocheFeb 200895
NCT01572038Breast Neoplasms · Algeria, Argentina, Australia and more3CompletedHoffmann-La RocheSep 20, 20191,436
NCT01565083Breast Neoplasms · United States, Brazil, Denmark and more2CompletedHoffmann-La RocheOct 2015213
NCT01491737Breast Neoplasms · United States, Brazil, France and more2CompletedHoffmann-La RocheMar 17, 2016258
NCT01461057Stomach Neoplasms · Belgium, Czechia, France and more2CompletedHoffmann-La RocheMar 1, 201530
NCT01358877Breast Neoplasms · United States, Argentina, Australia and more3CompletedHoffmann-La RocheDec 19, 20164,804
NCT01120184Breast Neoplasms · United States, Argentina, Australia and more3CompletedHoffmann-La RocheSep 30, 20141,095
NCT01026142Breast Neoplasms · Argentina, Austria, Belgium and more3CompletedHoffmann-La RocheMay 29, 2015452
NCT00976989Breast Neoplasms · Bahamas, Bosnia and Herzegovina, Brazil and more2CompletedHoffmann-La RocheJun 2011225
NCT00875979Breast Neoplasms · United States, Belgium, Canada and more2CompletedHoffmann-La RocheAug 201167
NCT00855894Carcinoma, Non-Small-Cell Lung · United States, Australia2CompletedHoffmann-La RocheMar 201241
NCT00567190Breast Neoplasms · United States, Argentina, Brazil and more3CompletedHoffmann-La RocheMay 13, 2011808
NCT00545688Breast Neoplasms · Australia, Austria, Brazil and more2CompletedHoffmann-La RocheSep 22, 2014417
NCT00096993Ovarian Neoplasms · United States2CompletedHoffmann-La RocheSep 2007131
NCT00096941Solid Cancers2CompletedHoffmann-La RocheOct 20073
NCT00063154Carcinoma, Non-Small-Cell Lung · United States2CompletedHoffmann-La RocheApr 200551
NCT00058552Ovarian Neoplasms2CompletedHoffmann-La RocheJul 2004129
NCT00058539Prostatic Neoplasms2CompletedHoffmann-La RocheOct 200442
NCT00027027Neoplasms · United States1CompletedHoffmann-La RocheAug 200321

How it is read

Names in the registry

  • “Pertuzumab”, 36 entries
  • “Pertuzumab IV”, 4 entries
  • “Perjeta”, 3 entries
  • “pertuzumab”, 2 entries
  • “RhuMab 2C4”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.